Isabella Ciccone, MPH

With new revisions of the MS diagnostic criteria being made, clinicians highlighted key updates and the broader implications it has for diagnosis, treatment, and healthcare practices worldwide.

As new treatments become available, it may be essential to achieve a timely and accurate diagnosis to enable patients and their family to make informed decisions and retain the greatest level of autonomy.

Adults with obstructive sleep apnea who receivied tirzepatide achieved an average of up to 20% weight loss and experienced at least 25 fewer breathing interruptions for each hour slept.

The professor of neurology at University of Florence talked about a study presented at ECTRIMS 2024 that validated definitions of progression independent of relapse activity in early relapsing MS. [WATCH TIME: 5 minutes]

Since the Syn-One Test only needs a small punch skin biopsy that can be collected in an office setting, the clinical utility can be enhanced to offer more geographically convenient access for patients earlier in the disease.

The investigational therapy was safe, well-tolerated, and showed promising improvements in cognitive measures among patients with dementia with Lewy bodies.

The program assembles a collaborative team of in-house and external experts in research, clinical care, and regulatory affairs to navigate gene therapy programs through the drug development process.

At AES 2024, a duo of pediatric epilepsy specialists discussed how implementation science, validated blood biomarkers, and cross-disciplinary collaboration are advancing epilepsy care and closing research gaps. [WATCH TIME: 3 minutes]

A duo from Child Neurology Foundation discussed advancing care, providing education for all stakeholders, and offering direct support to families, clinicians, and caregivers navigating neurological conditions for pediatric patients. [WATCH TIME: 5 minutes]

As of July 2024, 2 participants in the ongoing CONNECT1 study have received 4 doses of PGN-EDO51 at 10 mg/kg, which has been generally well tolerated, with initial results expected in early 2025.

The professor of neurology at NYU Grossman School of Medicine discussed a pioneering study using long seizure episodes to optimize treatment devices and identify effective antiseizure drugs in epilepsy care. [WATCH TIME: 2 minutes]

Most recently reported topline data from the RewinD-LB phase 2b trial in patients with dementia with Lewy bodies showed that neflamapimod failed to meet its primary end point and secondary end points.

At AES 2024, a duo of pediatric epilepsy specialists highlighted a Pediatric Epilepsy Research Consortium review on the need for standardized socio-demographic data and better follow-up for at-risk infants. [WATCH TIME: 5 minutes]

Findings from the ongoing PERSEUS phase 3 study of tolebrutinib in primary progressive multiple sclerosis are anticipated to be reported in the second half of 2025.

A duo from the Child Neurology Foundation discussed multidisciplinary collaboration, innovations in epilepsy care, and the importance of holistic, family-centric approaches to improving patient outcomes at AES 2024. [WATCH TIME: 5 minutes]

The professor of neurology at NYU Grossman School of Medicine discussed how innovative startups are using proof-of-concept studies and devices like responsive neurostimulators to improve patient outcomes. [WATCH TIME: 6 minutes]

The director of epilepsy surgery at Allegheny Health Network talked about recent advances in brain signal analysis with stereoelectroencephalography and its potential for transforming care for decision-making disorders. [WATCH TIME: 4 minutes]

The FDA recommended a follow-up meeting with Clene to further discuss the analyses needed to support the accelerated approval pathway for CNM-Au8 in amyotrophic lateral sclerosis.

The FDA has agreed that a scale used in ongoing phase 1/2 clinical trials could potentially serve as an intermediate clinical end point for accelerated approval pathway for uniQure’s investigational gene therapy AMT-130.

AbbVie recently announced that it is on track to submit the new drug application for its investigational Parkinson disease agent tavapadon to the FDA in 2025.

BIIB122 is a selective, central nervous system-penetrant small molecule that could potentially improve lysosomal dysfunction among patients with LRRK2-associated Parkinson disease.

The manager of the BARLO MS education program at St. Michael's Hospital highlighted the significance of recognition, the pivotal role of nurses in multiple sclerosis care, and the lasting impact of mentorship and advocacy. [WATCH TIME: 5 minutes]

The director of epilepsy surgery at Allegheny Health Network discussed how clinicians can successfully pinpoint the source of epilepsy in the brain through innovative procedures like stereo electroencephalography.

New data from the phase 3 SKYLINE study suggests soticlestat as a promising adjunctive therapy for seizures among children and young adults living with Dravet syndrome.

A new feature, in collaboration with NeurologyLive® and the International Journal of MS Care, brings perspectives from both the research and clinical community on women’s brain health as a subspecialty in neurology.

Krista L. Lanctôt, PhD, professor of psychiatry and pharmacology at the University of Toronto, talked about findings from a recent post hoc analysis presented at CTAD 2024 on nabilone for agitation in Alzheimer disease.

A recent study presented at AES 2024 revealed that plasma p-tau217 linked to memory decline and sleep disruptions in late-onset epilepsy, highlighting its potential as a biomarker.

The director of epilepsy surgery at Allegheny Health Network talked about research recently presented at AES 2024 on stereo-electroencephalography, a minimally invasive treatment for patients with epilepsy. [WATCH TIME: 7 minutes]

In a further date from the ongoing open-label extension of the phase 2b X-TOLE study, results demonstrated that the majority of treatment-emergent adverse events associated with azetukalner were mild or moderate.

A recent study presented at AES 2024 showed that fewer than 15% of doses of diazepam nasal spray administered to pediatric patients with epilepsy required a second dose in 24 hours.